Clinical Trial Update: Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical trial (AHA-PLUS) evaluating acetohydroxamic acid in combination with a short-course regimen for multidrug-resistant and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis
• Rifampicin-resistant Tuberculosis

Drugs mentioned

• Acetohydroxamic acid (acetohydroxamic acid)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 2 | Status: NOT_YET_RECRUITING